Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Stockholders' Equity

v3.22.2.2
Condensed Consolidated Statement of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Balance at beginning of period at Dec. 31, 2020 $ 142,706 $ 7 $ 819,549 $ 8 $ (676,858)
Balance at beginning of period (in shares) at Dec. 31, 2020   68,946,092      
Stock-based compensation expense 2,505   2,505    
Net loss (17,551)       (17,551)
Net unrealized gain (loss) on marketable securities (14)     (14)  
Balance at end of period at Mar. 31, 2021 127,646 $ 7 822,054 (6) (694,409)
Balance at end of period (in shares) at Mar. 31, 2021   68,946,092      
Balance at beginning of period at Dec. 31, 2020 142,706 $ 7 819,549 8 (676,858)
Balance at beginning of period (in shares) at Dec. 31, 2020   68,946,092      
Net loss (63,455)        
Net unrealized gain (loss) on marketable securities (9)        
Balance at end of period at Sep. 30, 2021 87,058 $ 7 827,365 (1) (740,313)
Balance at end of period (in shares) at Sep. 30, 2021   69,043,969      
Balance at beginning of period at Mar. 31, 2021 127,646 $ 7 822,054 (6) (694,409)
Balance at beginning of period (in shares) at Mar. 31, 2021   68,946,092      
Issuance of common stock upon exercise of stock options 106   106    
Issuance of common stock upon exercise of stock options (Shares)   51,846      
Stock-based compensation expense 2,557   2,557    
Net loss (23,222)       (23,222)
Net unrealized gain (loss) on marketable securities 7     7  
Balance at end of period at Jun. 30, 2021 107,094 $ 7 824,717 1 (717,631)
Balance at end of period (in shares) at Jun. 30, 2021   68,997,938      
Issuance of common stock upon exercise of stock options 99   99    
Issuance of common stock upon exercise of stock options (Shares)   46,031      
Stock-based compensation expense 2,549   2,549    
Net loss (22,682)       (22,682)
Net unrealized gain (loss) on marketable securities (2)     (2)  
Balance at end of period at Sep. 30, 2021 87,058 $ 7 827,365 (1) (740,313)
Balance at end of period (in shares) at Sep. 30, 2021   69,043,969      
Balance at beginning of period at Dec. 31, 2021 132,937 $ 8 899,798 (13) (766,856)
Balance at beginning of period (in shares) at Dec. 31, 2021   84,677,939      
Issuance costs related to issuance of common stock and pre funded warrants shares (Shares)   0      
Issuance costs related to issuance of common stock and pre funded warrants 5   5    
Stock-based compensation expense 2,414   2,414    
Net loss (27,769)       (27,769)
Net unrealized gain (loss) on marketable securities (206)     (206)  
Balance at end of period at Mar. 31, 2022 107,381 $ 8 902,217 (219) (794,625)
Balance at end of period (in shares) at Mar. 31, 2022   84,677,939      
Balance at beginning of period at Dec. 31, 2021 132,937 $ 8 899,798 (13) (766,856)
Balance at beginning of period (in shares) at Dec. 31, 2021   84,677,939      
Net loss (79,368)        
Net unrealized gain (loss) on marketable securities (561)        
Balance at end of period at Sep. 30, 2022 60,178 $ 8 906,968 (574) (846,224)
Balance at end of period (in shares) at Sep. 30, 2022   84,681,063      
Balance at beginning of period at Mar. 31, 2022 107,381 $ 8 902,217 (219) (794,625)
Balance at beginning of period (in shares) at Mar. 31, 2022   84,677,939      
Stock-based compensation expense 2,392   2,392    
Net loss (27,094)       (27,094)
Net unrealized gain (loss) on marketable securities (222)     (222)  
Balance at end of period at Jun. 30, 2022 82,457 $ 8 904,609 (441) (821,719)
Balance at end of period (in shares) at Jun. 30, 2022   84,677,939      
Issuance of common stock upon exercise of stock options 9   9    
Issuance of common stock upon exercise of stock options (Shares)   3,124      
Stock-based compensation expense 2,350   2,350    
Net loss (24,505)       (24,505)
Net unrealized gain (loss) on marketable securities (133)     (133)  
Balance at end of period at Sep. 30, 2022 $ 60,178 $ 8 $ 906,968 $ (574) $ (846,224)
Balance at end of period (in shares) at Sep. 30, 2022   84,681,063